-
8/13/2019 General IB Sd
1/8
Investigator Brouchure (I.B.)
Suman Sehrawat
-
8/13/2019 General IB Sd
2/8
Investigator Brouchure
The Investigator's Brochure (I.B.) is the handbook of
theinvestigator carrying out safe and successful clinical trial
I.B. is a compilation of the clinical and nonclinical data
on
the investigational product(s) that are relevant to the studyof
the product(s) in human subjects.
1
-
8/13/2019 General IB Sd
3/8
Purpose of I.B.
Its purpose is to provide Information to the investigatorsand
others involved in the trial such as the dose, dose
frequency/interval, methods of administration: and safety
monitoring procedures.
The IB also provides insight to support the clinicalmanagement
of the study subjects during the course of the
clinical trial. The information should be presented in a
concise and simple manner.
It enables a clinician, or potential investigator, tounderstand
it and make his/her own unbiased risk-benefit
assessment of the appropriateness of the proposed trial.
For this reason, a medically qualified person should
generally participate in the editing of an IB.
2
-
8/13/2019 General IB Sd
4/8
Contents of I.B.
The Investigator Brochure should include:Title Page
This section contains the sponsor's name, the identity of
each
investigational product (i.e., research number, chemical or
approved
generic name, and trade name(s) where legally permissible and
desired
by the sponsor), and the release date.Confidentiality
Statement
The sponsor may wish to include a statement instructing the
investigator/recipients to treat the IB as a confidential
document
Summary
A brief summary should be given, highlighting the significant
physical,
chemical, pharmaceutical, pharmacological, toxicological,
pharmacokinetic, metabolic, and clinical information
available
3
-
8/13/2019 General IB Sd
5/8
Contents of I.B.
Description of I.P.Physical, chemical and pharmaceutical
properties of I.P.
Storage and handling of I.P.
Any structural similarity with the other known compound
given
Non Clinical Studies
The results of all relevant nonclinical pharmacology,
toxicology,
pharmacokinetic, and investigational product metabolism
studies
should be provided in summary form.
The information provided may include: Species tested, number of
sexin each group, Unit dose (e.g., milligram/kilogram (mg/kg),
dose
interval, route of administration and duration of dosing.
4
-
8/13/2019 General IB Sd
6/8
Contents of I.B.
Non Clinical Study Types: Nonclinical Pharmacology
A summary of the pharmacological aspects of the investigational
product
studied in animals, should be included.
Pharmacokinetics and Product Metabolism in Animals
A summary of the pharmacokinetics(ADME) and biological
transformation
and disposition (getting a drug into its appropriate position in
the body and
in an appropriate concentration) of the investigational product
in all
species studied should be given.
Toxicology (The study of the adverse effects of chemicals
onanimals)
A summary of the toxicological effects found in relevant studies
conducted
in different animal species.
5
-
8/13/2019 General IB Sd
7/8
Contents of I.B.
Effects in Humans A thorough discussion of the known effects of
the investigational
product(s) in humans should be provided, including information
on
pharmacokinetics, metabolism, Pharmacodynamics, dose
response,
safety, efficacy, and other pharmacological activities.
(a) Pharmacokinetics and Product Metabolism in Humans A summary
of information on the pharmacokinetics of the
investigational product(s) should be presented.
(b) Safety and Efficacy
A summary of information should be provided about the
investigational
product's safety, efficacy, pharmacodynamics
(c) Marketing Experience
The IB should identify countries where the investigational
product has
been marketed or approved.
6
-
8/13/2019 General IB Sd
8/8
Contents of I.B.
Summary of Data and Guidance for the InvestigatorThis section
should contain nonclinical and clinical data of IP.
7
